Latest Savient Pharmaceuticals Inc (SVNTQ) Headlin
Post# of 5
Posted On: 03/13/2014 3:06:08 AM
Latest Savient Pharmaceuticals Inc (SVNTQ) Headlines
DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of Savient Pharmaceuticals, Inc. Of Upcoming Deadline
Business Wire - Mon Mar 10, 3:01PM CDT
Rigrodsky & Long, P.A.:
Rigrodsky & Long, P.A. Files Securities Fraud Class Action Lawsuit Against Certain Executives And Directors Of Savient Pharmaceuticals, Inc.
Business Wire - Tue Jan 21, 1:03PM CST
Rigrodsky & Long, P.A.:
Crealta Pharmaceuticals LLC Announces Completion of the Acquisition of Substantially All of the Assets of Savient Pharmaceuticals, Inc.
PR Newswire - Fri Jan 10, 6:00AM CST
Crealta Pharmaceuticals LLC ("Crealta"), a new specialty pharmaceutical company, announced today the completion of the acquisition of substantially all of the assets of Savient Pharmaceuticals, Inc. ("Savient"). Crealta previously announced the winning of an auction for these assets, the signing of a definitive acquisition agreement with Savient, and the subsequent approval of the transaction by the U.S. Bankruptcy Court for the District of Delaware.
Savient Receives Approval From Bankruptcy Court To Sell Substantially All Assets To Crealta Pharmaceuticals
PR Newswire - Fri Dec 13, 11:07AM CST
Savient Pharmaceuticals, Inc. (OTC: SVNTQ) ("Savient") announced today that it has received approval from the U.S. Bankruptcy Court for the District of Delaware (the "Court") to sell substantially all of the assets of Savient, including all KRYSTEXXA® assets, to Crealta Pharmaceuticals LLC ("Crealta").
Savient Pharma plans asset sale to Crealta
AP - Wed Dec 11, 7:42AM CST
BRIDGEWATER, N.J. (AP) — Savient Pharmaceuticals Inc. plans to sell its drug portfolio, including the gout treatment Krystexxa, to Crealta Pharmaceuticals LLC for $120.4 million, pending bankruptcy court approval.
Savient Reaches Agreement To Sell Substantially All Assets To Crealta Pharmaceuticals
PR Newswire - Wed Dec 11, 6:00AM CST
Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) ("Savient") announced today that it has reached agreement on the terms of an acquisition agreement with Crealta Pharmaceuticals LLC ("Crealta") through which Crealta would acquire substantially all of the assets of Savient, including all KRYSTEXXA® assets, for gross proceeds of approximately $120.4 million. The agreement was reached following an auction conducted pursuant to bidding procedures approved by the U.S. Bankruptcy Court for the District of Delaware (the "Court"). A hearing at which Savient and Crealta will seek the required Court approval of the sale is scheduled for Friday, December 13, 2013.
Savient Reaches Agreement On Use Of Cash Collateral
PR Newswire - Mon Dec 09, 11:28PM CST
Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) ("Savient") announced today that an agreement in principle has been reached by and among Savient, the Official Committee of Unsecured Creditors appointed in Savient's Chapter 11 case (the "UCC") and the Unofficial Committee of Senior Secured Noteholders (the "Unofficial Committee" and, together with Savient and the UCC, the "Parties"), whose members hold approximately 90% of Savient's senior secured notes (the "Secured Noteholders"). As part of the agreement, it is anticipated that the UCC will withdraw its objection and consent to entry of a final order authorizing Savient's continued use of cash collateral (the "Final Cash Collateral Order") by the U.S. Bankruptcy Court for the District of Delaware (the "Court"). The Parties anticipate submitting a proposed Final Cash Collateral Order for consideration and approval by the Court on or before the hearing to consider the Final Cash Collateral Order, currently scheduled to take place on December 13, 2013 (subject to such notice procedures as may be agreed by the Parties). If entered by the Court, the proposed Final Cash Collateral Order would, among other things, provide for the distribution of proceeds from the sale of all or substantially all of Savient's assets (the "Sale") and of additional amounts of cash collateral to the Secured Noteholders promptly after the Sale closing. The agreement further contemplates that the UCC would waive its rights to challenge the Secured Noteholders' liens and claims subject to the implementation of a global settlement between Savient, the UCC and the Unofficial Committee (the "Proposed Settlement"). The Proposed Settlement, which remains subject to documentation and final agreement by the Parties and is to be separately submitted for approval by the Court at a later date, is anticipated to include the following principal terms (but may be amended or modified by agreement of the Parties):
Gouty Arthritis (Gout) Global Clinical Trials Review, H2, 2013 Out Now for Review
M2 - Tue Nov 19, 10:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/p3xkbz/gouty_arthritis) has announced the addition of the "Gouty Arthritis (Gout) Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Gouty Arthritis (Gout) Global Clinical Trials Review, H2, 2013" provides data on the Gouty Arthritis (Gout) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Gouty Arthritis (Gout). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Gouty Arthritis (Gout). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies Mentioned: AstraZeneca PLC Takeda Pharmaceutical Company Limited Novartis AG Mutual Pharmaceutical Company, Inc. Regeneron Pharmaceuticals, Inc. Savient Pharmaceuticals, Inc. Fuji Yakuhin Co., Ltd. Sanwa Kagaku Kenkyusho Co., Ltd. BioCryst Pharmaceuticals, Inc. Metabolex, Inc Zhejiang University Royal Perth Hospital The University of Mississippi Medical Center University of Otago University of Toronto The University of Nottingham St Vincent's Hospital Sydney The Medical Center Leeuwarden Midorigaoka Hospital Kobe University For more information visit http://www.researchandmarkets.com/research/p3..._arthritis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of Savient Pharmaceuticals, Inc. Of Upcoming Deadline
Business Wire - Mon Mar 10, 3:01PM CDT
Rigrodsky & Long, P.A.:
Rigrodsky & Long, P.A. Files Securities Fraud Class Action Lawsuit Against Certain Executives And Directors Of Savient Pharmaceuticals, Inc.
Business Wire - Tue Jan 21, 1:03PM CST
Rigrodsky & Long, P.A.:
Crealta Pharmaceuticals LLC Announces Completion of the Acquisition of Substantially All of the Assets of Savient Pharmaceuticals, Inc.
PR Newswire - Fri Jan 10, 6:00AM CST
Crealta Pharmaceuticals LLC ("Crealta"), a new specialty pharmaceutical company, announced today the completion of the acquisition of substantially all of the assets of Savient Pharmaceuticals, Inc. ("Savient"). Crealta previously announced the winning of an auction for these assets, the signing of a definitive acquisition agreement with Savient, and the subsequent approval of the transaction by the U.S. Bankruptcy Court for the District of Delaware.
Savient Receives Approval From Bankruptcy Court To Sell Substantially All Assets To Crealta Pharmaceuticals
PR Newswire - Fri Dec 13, 11:07AM CST
Savient Pharmaceuticals, Inc. (OTC: SVNTQ) ("Savient") announced today that it has received approval from the U.S. Bankruptcy Court for the District of Delaware (the "Court") to sell substantially all of the assets of Savient, including all KRYSTEXXA® assets, to Crealta Pharmaceuticals LLC ("Crealta").
Savient Pharma plans asset sale to Crealta
AP - Wed Dec 11, 7:42AM CST
BRIDGEWATER, N.J. (AP) — Savient Pharmaceuticals Inc. plans to sell its drug portfolio, including the gout treatment Krystexxa, to Crealta Pharmaceuticals LLC for $120.4 million, pending bankruptcy court approval.
Savient Reaches Agreement To Sell Substantially All Assets To Crealta Pharmaceuticals
PR Newswire - Wed Dec 11, 6:00AM CST
Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) ("Savient") announced today that it has reached agreement on the terms of an acquisition agreement with Crealta Pharmaceuticals LLC ("Crealta") through which Crealta would acquire substantially all of the assets of Savient, including all KRYSTEXXA® assets, for gross proceeds of approximately $120.4 million. The agreement was reached following an auction conducted pursuant to bidding procedures approved by the U.S. Bankruptcy Court for the District of Delaware (the "Court"). A hearing at which Savient and Crealta will seek the required Court approval of the sale is scheduled for Friday, December 13, 2013.
Savient Reaches Agreement On Use Of Cash Collateral
PR Newswire - Mon Dec 09, 11:28PM CST
Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) ("Savient") announced today that an agreement in principle has been reached by and among Savient, the Official Committee of Unsecured Creditors appointed in Savient's Chapter 11 case (the "UCC") and the Unofficial Committee of Senior Secured Noteholders (the "Unofficial Committee" and, together with Savient and the UCC, the "Parties"), whose members hold approximately 90% of Savient's senior secured notes (the "Secured Noteholders"). As part of the agreement, it is anticipated that the UCC will withdraw its objection and consent to entry of a final order authorizing Savient's continued use of cash collateral (the "Final Cash Collateral Order") by the U.S. Bankruptcy Court for the District of Delaware (the "Court"). The Parties anticipate submitting a proposed Final Cash Collateral Order for consideration and approval by the Court on or before the hearing to consider the Final Cash Collateral Order, currently scheduled to take place on December 13, 2013 (subject to such notice procedures as may be agreed by the Parties). If entered by the Court, the proposed Final Cash Collateral Order would, among other things, provide for the distribution of proceeds from the sale of all or substantially all of Savient's assets (the "Sale") and of additional amounts of cash collateral to the Secured Noteholders promptly after the Sale closing. The agreement further contemplates that the UCC would waive its rights to challenge the Secured Noteholders' liens and claims subject to the implementation of a global settlement between Savient, the UCC and the Unofficial Committee (the "Proposed Settlement"). The Proposed Settlement, which remains subject to documentation and final agreement by the Parties and is to be separately submitted for approval by the Court at a later date, is anticipated to include the following principal terms (but may be amended or modified by agreement of the Parties):
Gouty Arthritis (Gout) Global Clinical Trials Review, H2, 2013 Out Now for Review
M2 - Tue Nov 19, 10:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/p3xkbz/gouty_arthritis) has announced the addition of the "Gouty Arthritis (Gout) Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Gouty Arthritis (Gout) Global Clinical Trials Review, H2, 2013" provides data on the Gouty Arthritis (Gout) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Gouty Arthritis (Gout). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Gouty Arthritis (Gout). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies Mentioned: AstraZeneca PLC Takeda Pharmaceutical Company Limited Novartis AG Mutual Pharmaceutical Company, Inc. Regeneron Pharmaceuticals, Inc. Savient Pharmaceuticals, Inc. Fuji Yakuhin Co., Ltd. Sanwa Kagaku Kenkyusho Co., Ltd. BioCryst Pharmaceuticals, Inc. Metabolex, Inc Zhejiang University Royal Perth Hospital The University of Mississippi Medical Center University of Otago University of Toronto The University of Nottingham St Vincent's Hospital Sydney The Medical Center Leeuwarden Midorigaoka Hospital Kobe University For more information visit http://www.researchandmarkets.com/research/p3..._arthritis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
(0)
(0)Savient Pharmaceuticals Inc (SVNTQ) Stock Research Links
Scroll down for more posts ▼